Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

BackgroundCD40, a key co-stimulatory molecule expressed on antigen-presenting cells, is genetically associated with a number of autoimmune diseases including Graves’ disease (GD). Therefore, recent therapies targeting CD40 have been developed, including the anti-CD40 monoclonal antibody Iscalimab. I...

Full description

Bibliographic Details
Main Authors: Larissa C. Faustino, George J. Kahaly, Lara Frommer, Erlinda Concepcion, Mihaela Stefan-Lifshitz, Yaron Tomer
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Endocrinology
Subjects:
gene
CD40
variant
Graves’ disease
precision medicine
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.691781/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.691781/full

Similar Items